WithdrawnNot Applicable

Expression of Sodium-glucose Co-transporter 2 in Human Heart

Stopped: authorization obsolete

France0Started 2023-06

Plain-language summary

The aim of the study is to evaluate the expression of Sodium Glucose Co-transporter 2 (SGLT2) in myocardium from patients with aortic stenosis. 2 groups of patients will be defined: Group A with diastolic heart failure and Group B without heart failure. The expression of SGLT2 will be measured on small myocardium specimens harvested during aortic valve replacement operation. This study should allow us to better understand the effect of glifozines in human heart failure.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * adults over 18 years-old * Patient with surgical aortic valve stenosis, with or without heart failure, in two equal-sized groups (40 subjects in each group) * Subjects affiliated with a social security health insurance plan * Subject able to understand the objectives and risks of the research and to give dated and signed informed consent Exclusion Criteria: * Infective endocarditis in aortic stenosis * Severe coronary pathology associated with aortic stenosis * Impossible to give the subject informed information (subject in emergency situation, difficulties in understanding the subject, ...) * Subject under legal protection * Subject under guardianship or curatorship * Pregnancy and/or breastfeeding

What they're measuring

To study the expression levels of SGLT2 in the myocardium of patients with surgical aortic stenosis

Timeframe: Day 0

To study the SGLT2 tissue localization in the myocardium of patients with surgical aortic stenosis

Timeframe: Day 0

Trial details

NCT IDNCT05830760

SponsorUniversity Hospital, Strasbourg, France

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-10